Augmented Transdermal Delivery of Curcumin for the Effective Management of Plaque Psoriasis – Design, Formulation, Characterisation, and In Vivo Studies
Abstract Psoriasis is a recurrent, life-threatening anti-inflammatory condition that affects nearly 1–3% of the global population. It is an autoimmune illness distinguished by hyperplasia of skin cells or fast skin cell development, resulting in abnormally irritating scales and skin patches. Curcumin, as a selective phosphorylase kinase inhibitor, actively suppresses inflammation and keratinocyte proliferation in psoriasis. However, limited solubility in water and poor skin permeability poses a significant hurdle in curcumin’s topical effectiveness in psoriasis. The present study focuses on enhancing the solubility and skin permeability of curcumin for better transdermal application. Curcumin-loaded invasomes were formulated, and a factorial design was applied to study the effect of the type of terpenes and their concentrations on the properties of prepared invasomes. A topical gel was formulated using the optimised invasomal formulation which was further evaluated for anti-psoriatic potential in BALB/c mice. The optimised formulation showed 85.84 ± 0.56% entrapment efficiency and a vesicle size of 302.33 ± 1.53 nm. The invasomal gel of the optimised formulation showed a permeation flux of 3 times greater than the plain gel. In vivo studies demonstrated that the invasomal gel of curcumin promoted faster and earlier recovery in psoriatic mice than conventional curcumin gel..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
AAPS PharmSciTech - 24(2023), 5 vom: 08. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kumar, Bhumika [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1208/s12249-023-02595-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051839458 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051839458 | ||
| 003 | DE-627 | ||
| 005 | 20230623064758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1208/s12249-023-02595-8 |2 doi | |
| 035 | |a (DE-627)SPR051839458 | ||
| 035 | |a (SPR)s12249-023-02595-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kumar, Bhumika |e verfasserin |0 (orcid)0000-0002-4127-4492 |4 aut | |
| 245 | 1 | 0 | |a Augmented Transdermal Delivery of Curcumin for the Effective Management of Plaque Psoriasis – Design, Formulation, Characterisation, and In Vivo Studies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Psoriasis is a recurrent, life-threatening anti-inflammatory condition that affects nearly 1–3% of the global population. It is an autoimmune illness distinguished by hyperplasia of skin cells or fast skin cell development, resulting in abnormally irritating scales and skin patches. Curcumin, as a selective phosphorylase kinase inhibitor, actively suppresses inflammation and keratinocyte proliferation in psoriasis. However, limited solubility in water and poor skin permeability poses a significant hurdle in curcumin’s topical effectiveness in psoriasis. The present study focuses on enhancing the solubility and skin permeability of curcumin for better transdermal application. Curcumin-loaded invasomes were formulated, and a factorial design was applied to study the effect of the type of terpenes and their concentrations on the properties of prepared invasomes. A topical gel was formulated using the optimised invasomal formulation which was further evaluated for anti-psoriatic potential in BALB/c mice. The optimised formulation showed 85.84 ± 0.56% entrapment efficiency and a vesicle size of 302.33 ± 1.53 nm. The invasomal gel of the optimised formulation showed a permeation flux of 3 times greater than the plain gel. In vivo studies demonstrated that the invasomal gel of curcumin promoted faster and earlier recovery in psoriatic mice than conventional curcumin gel. | ||
| 650 | 4 | |a curcumin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a invasomes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a terpene |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a gel |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a imiquimod |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a plaque psoriasis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Sahoo, Pravat Kumar |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d New York, NY : Springer, 2000 |g 24(2023), 5 vom: 08. Juni |w (DE-627)SPR02478785X |w (DE-600)2052070-0 |x 1530-9932 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:5 |g day:08 |g month:06 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12249-023-02595-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 5 |b 08 |c 06 | ||